Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4590 Association of SST5TMD4 and SST5TMD5 expression with metastasis and poor prognostic markers in gastroenteropancreatic neuroendocrine tumours

Introduction: The expression of the somatostatin receptor isoform SST5TMD4 is linked to poorer prognosis in somatotropinomas, as well as in breast and thyroid cancers, and it is notably overexpressed in gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Conference:

Presenting Author: Pedraza-Arevalo S

Authors: Pedraza-Arévalo S, Díaz-Pérez J, Garcia-Carbonero R, Villabona C, Capdevila J,

Keywords: GEP-NET, somatostatin, truncated receptor, metastasis,

#4507 Biliary complications for metastatic patients with neuroendocrine tumours of the pancreatic head and their influence on survival: Is it necessary to change the current management?

Introduction: Neuroendocrine tumours of the pancreatic head (NETPH) can be associated with local complications. At the metastatic stage, surgery of the primary tumour (PT) is not a standard of care. But the biliary complications (BC) due to the untreated NETPH may complicate the management and deteriorate the prognosis.

Conference:

Presenting Author: Ujlaki G

Authors: Ujlaki G, Fernandez de Sevilla E, Moog S, Lamartina L, Hadoux J,

Keywords: neuroendocrine, pancreatic head, metastatic, biliary complications,

#3644 N-terminal pro-brain natriuretic peptide and chromogranin A as biomarkers for detection of carcinoid heart disease

Introduction: Carcinoid heart disease (CHD) is a serious complication for patients with neuroendocrine tumors (NETs), and early detection is crucial.

Conference:

Presenting Author: Lau T

Authors: Lau T, Johnson K, Oksjoki R, Baunwall S, Villadsen G,

Keywords: carcinoid heart disease, probnp, 5-hiaa, cga, biomarker,

#3569 Outcomes of Streptozotocin (STZ)-based chemotherapy (CT) in patients with advanced pancreatic neuroendocrine tumors (pNETs): Data from the Spanish Taskforce of Neuroendocrine and Endocrine Tumors (GETNE) national registry (R-GETNE)

Introduction: STZ-based CT has been used for advanced pNETs with rapid growth, high tumor load or progression to somatostatin analogues (SSA). Evidence supporting use of STZ-based CT in pNET is mainly retrospective, and there is an unmet need of prospective trials in this setting. We present data from the R-GETNE regarding the use of STZ in spanish centers.

Conference:

Presenting Author:

Authors: Esteban-Villarrubia J, Hernando J, Garcia A, Jimenez-Fonseca P, Teulé A,

Keywords: Streptozotocin, Chemotherapy, pNET, GETNE, R-GETNE,

#3563 Can tumor absorbed dose predict response to Peptide Receptor Radionuclide Therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)?

Introduction: Tumor dosimetry protocols following Peptide Receptor Radionuclide Therapy (PRRT) have not yet been standardised and tumor absorbed dose does not hold clear value in predicting response to treatment.

Conference:

Presenting Author: Mileva M

Authors: Mileva M, Marin G, Levillain H, van Bogaert C, Critchi G,

Keywords: PRRT, tumor dose, 68Ga-DOTATATE, SUVmax, response,